Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Clinical trial NCT07622706 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07622706
Sponsor: Peking University Cancer Hospital & Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC EGFR Positive Non-small Cell Lung Cancer Neoadjuvant Therapy

Start date: 2026-05-30
Primary completion: 2028-05-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.